ReviewSeminars in respiratory and critical care medicine2008
Epidemiology and treatment of multidrug resistant tuberculosis.
Review in Seminars in respiratory and critical care medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Isothermal Amplification of Nucleic Acids Coupled with Nanotechnology and Microfluidic Platforms for Detecting Antimicrobial Drug Resistance and Beyond.Advanced pharmaceutical bulletin · 2022Review
- The burden of drug resistant tuberculosis in a predominantly nomadic population in Uganda: a mixed methods study.BMC infectious diseases · 2021Article
- Bayesian Spatial Survival Analysis of Duration to Cure among New Smear-Positive Pulmonary Tuberculosis (PTB) Patients in Iran, during 2011-2018.International journal of environmental research and public health · 2020Article
- An audiological profile of patients infected with multi-drug resistant tuberculosis at a district hospital in KwaZulu-Natal.The South African journal of communication disorders = Die Suid-Afrikaanse tydskrif vir Kommunikasieafwykings · 2016Article
- Rolling circle amplification for direct detection of rpoB gene mutations in Mycobacterium tuberculosis isolates from clinical specimens.Journal of clinical microbiology · 2014Article
- Hopelessness as a basis for tuberculosis diagnostic delay in the Arkhangelsk region: a grounded theory study.BMC public health · 2013Article
- Impact of rapid drug susceptibility testing for tuberculosis: program experience in Lima, Peru.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2012Article
- Rapid detection of rpoB gene mutations conferring rifampin resistance in Mycobacterium tuberculosis.Journal of clinical microbiology · 2012Article
- Patterns of antituberculous drug resistance in Eastern Saudi Arabia: a 7-year surveillance study from 1/2003 to 6/2010.Journal of epidemiology and global health · 2012Article
- Induction of β-defensins by l-isoleucine as novel immunotherapy in experimental murine tuberculosis.Clinical and experimental immunology · 2011Article
- Targeted drug-resistance testing strategy for multidrug-resistant tuberculosis detection, Lima, Peru, 2005-2008.Emerging infectious diseases · 2011Article
- Article
- Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis.Nature reviews. Microbiology · 2009Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Multidrug resistant tuberculosis is now thought to afflict between 1 and 2 million patients annually. Although significant regional variability in the distribution of disease has been recorded, surveillance data are limited by several factors. The true burden of disease is likely underestimated. Nevertheless, the estimated burden is substantial enough to warrant concerted action. A range of approaches is possible, but all appropriate interventions require scale-up of laboratories and early treatment with regimens containing a sufficient number of second-line drugs. Ambulatory treatment for most patients, and improved infection control, can facilitate scale-up with decreased risk of nosocomial transmission. Several obstacles have been considered to preclude worldwide scale-up of treatment, mostly attributable to inadequate human, drug, and financial resources. Further delays in scale-up, however, risk continued generation and transmission of resistant tuberculosis, as well as associated morbidity and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.